---
document_datetime: 2023-12-12 14:02:27
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/vyepti-epar-all-authorised-presentations_en.pdf
document_name: vyepti-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.8739148
conversion_datetime: 2025-12-17 15:23:46.798776
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical Form                   | Route of Administration   | Immediate Packaging   | Content (concentration)   | Pack size   |
|------------------|-------------------|------------|---------------------------------------|---------------------------|-----------------------|---------------------------|-------------|
| EU/1/21/1599/001 | Vyepti            | 100 mg     | Concentrate for solution for infusion | Intravenous use           | vial (glass)          | 1 ml (100mg/ml)           | 1 vial      |
| EU/1/21/1599/002 | Vyepti            | 100 mg     | Concentrate for solution for infusion | Intravenous use           | vial (glass)          | 1 ml (100mg/ml)           | 3 vials     |
| EU/1/21/1599/003 | Vyepti            | 300 mg     | Concentrate for solution for infusion | Intravenous use           | vial (glass)          | 3 ml (100 mg/ml)          | 1 vial      |